FDA approves Duopa (carbidopa + levodopa suspension) for advanced Parkinsons Disease-AbbVie
The FDA has approved AbbVie's Duopa (carbidopa and levodopa) enteral suspension for the treatment of motor fluctuations for people with advanced Parkinson's Disease. Duopa is administered using a small, portable infusion pump that delivers carbidopa and levodopa directly into the small intestine for 16 continuous hours via a procedurally-placed tube. Duopa was approved by the FDA as an orphan drug, a designation granted to products intended for the treatment of rare diseases or conditions affecting fewer than 200,000 patients in the U.S.
Comment: In clinical trials, Duopa was shown to significantly reduce the amount of "off time" experienced by patients with advanced Parkinson's Disease ."Off" time refers to the periods of poor mobility, slowness and stiffness experienced by patients with the disease.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins